Comparative significance of p53 and WAF/1-P21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas

Pancreas

Volumn 18, Issue 2, 1999, Pages 117-126

  Nio, Yoshinori ^a   Dong, Ming ^a   Uegaki, Ken ^a   Hirahara, Noriyuki ^a   Minari, Yoshimitsu ^a   Sasaki, Susumu ^a   Takamura, Michio ^a   Iguchi, Chikage ^a   Tamura, Katsuhiro ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cyclophosphamide; P53; Pancreatic cancer; UFT; WAF 1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; MONOCLONAL ANTIBODY; PROTEIN P21; PROTEIN P53; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0032902994     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199903000-00002     Document Type: Article

References (53)

1. Finlay C, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
2. Jenkins JR, Rudge K, Chumakov P, Currie GA. The cellular oncogene p53 can be activated by mutagenesis. Nature 1985;317: 816-8.
3. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
4. Bartek J, Bartokova J, Vojtesek B. et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
5. Porter PL, Grown AM, Kramp SG, Coltera MD. Widespread p53 over expression in human malignant tumors: an immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992;140:145-53.
6. Wu XW, Bayle H, Olsen D, Levine AJ. The p53-MDM-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
8. El-Deiry WS, Takahashi T, Velcculescu VE, et al. WAF1: a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
9. 1 cycline-dependent kinases. Cell 1993;75:805-16.
10. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
11. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.
12. Benhattar J, Cerottini JP, Saraga E, Merrez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996;69:190-2.
13. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28.
14. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.
15. Petty RD, Cree IA, Sutherland LA, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 1994;28:264-70.
16. Muller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16: 3845-8.
17. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62.
18. Iwaya K, Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82 835-45.
19. Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 1995;75:2037-44.
20. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993;55:51-6.
21. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84: 883-7.
22. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
23. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
24. Mclaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735-8.
25. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-9.
26. Motojima K, Furui J, Kohara N, Ito T, Kanematsu T. Expression of p53 protein in gastric carcinoma is not independently prognostic. Surgery 1994;116:890-5.
27. Byrne RL, Wilson, Home CH, et al. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997;79:190-5.
28. Boston GJ, Gillespie J, Guillou PJ. Biology of pancreatic cancer. Gut 1991;32:800-12.
29. Lemoine NR, Hall PA. Growth factors and oncogenes in pancreatic cancer. Baillieres Clin Gastroenterol 1990;4:815-32.
30. Bos JL. ras Oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
31. Almoguera C, Shibata D, Forrester K, Martin J, Peerucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
32. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
33. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
34. Casey G, Yamanaka Y, Friess H, et al. p53 gene mutations are common in pancreatic cancer and absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
35. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994;14:2477-84.
36. Nakamori S, Yashima K, Murakami Y, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-81.
37. Zhang SY, Ruggeri B, Agarwal P, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994;118:150-4.
38. Sinicrope FA, Evans DB, Leach SD, et al. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 1996;2:2015-22.
39. Lee CS, Rush M, Charalambous D, Rode J. Immunohistochemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 1993;8:465-9.
40. Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, p21/WAF-1 genes in sporadic and familial lesions. Cancer 1997;79:700-16.
41. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in - pancreatic adenocarcinoma. Int J Pancreatol 1997;21:127-43.
42. American Joint Committee on Cancer, TNM Committee of the International Union Against Cancer. Staging of cancer from the manual for staging of cancer, 5th ed. 1997.
43. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
44. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
45. Wilcock D, Lane DP. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature 1991;349:429-31.
46. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
47. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence? J Natl Cancer Inst 1993;85:1154-7.
48. Hoshi T, Imai M, Ogawa K. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol 1994;55:84-91.
49. Sato Y, Nio Y, Song M, Sumi S, Hirahara N, Minari Y, Tamura K. p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res 1997;17:2779-88.
50. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996;53:104-11.
51. Loehre PJ, Williams SD, Einhorn LH, et al. An active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 1985; 3:367-72.
52. Wils JA. Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 1989;9:1027-32.
53. Arbuck SG. Chemotherapy for pancreatic cancer. Baillieres Clin Gastroenterol 1990;4:953-68.